Trial Profile
Phase I evaluation of safety of intravenous infusion of a pathotropic vector bearing a cytocidal cyclin G1 construct (Rexin-G) as intervention for locally advanced and metastatic pancreatic cancer refractory to standard chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rexin-G (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Epeius Biotechnologies Corporation
- 13 Feb 2006 New trial record.